← Leaderboards
Mark Dovey
Children'S Hospital Boston
$100,085
Attributed
$100,085
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$100,085 · 3
By mechanism
M01$100,085 · 3
Top collaborators
No co-investigators on record.
Most similar at Children'S Hospital Boston
Same institution · by research overlap
- David A Waltz$84,936
- Claudia Ordonez$792,047
- Craig J. Gerard$12,629,224
- William E. Harmon$17,038,662
- Mary E Wohl$1,334
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationHuman SubjectCystic FibrosisGene TherapyPolymerase Chain ReactionClinical Trial Phase IAdeno Associated Virus GroupRespiratory TherapyRecombinant VirusUrinalysisDrug Administration Rate /DurationDrug Screening /EvaluationDisease /Disorder ClassificationHuman DataCorticosteroidsCombination TherapyLeukotrienesLipoxygenaseLongitudinal Human StudyLungLung DisorderMetabolism Disorder ChemotherapyOral Administration
Grant awards (6)
Placebo-controlled oral corticosteroid therapy in CF patients$99,418
M01 · FY2004 · RR
AEROSOLIZED TGAAVCF FOR TREATMENT OF CYSTIC FIBROSIS$0
M01 · FY2002 · RR
AEROSOLIZED TGAAVCF FOR TREATMENT OF CYSTIC FIBROSIS$0
M01 · FY2001 · RR
AEROSOLIZED TGAAVCF FOR TREATMENT OF CYSTIC FIBROSIS$0
M01 · FY2001 · RR
URINARY LEUKOTRIENE E4 LEVELS AS MARKER OF PULMONARY DISEASE PROGRESSION IN CF$667
M01 · FY2000 · RR
AEROSOLIZED TGAAVCF FOR TREATMENT OF CYSTIC FIBROSIS$0
M01 · FY2000 · RR